Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Psilocybin/Borderline Personality Disorder (BPD)

Psilocybin for Borderline Personality Disorder (BPD)

3 papers and 1 clinical trial exploring psilocybin as a treatment for borderline personality disorder (bpd).

CompoundClassic Psychedelic

Psilocybin

Psilocybin is a naturally occurring tryptamine psychedelic that acts as a prodrug to psilocin, a potent 5-HT2A receptor agonist. It is the furthest advanced psychedelic in clinical development, with two positive Phase III trials in treatment-resistant depression and expanding regulated access in Australia, Germany, and US states.

Full Psilocybin profile
Indication1.8% of adults globally.

Borderline Personality Disorder (BPD)

Research into psychedelic-assisted therapies for Borderline Personality Disorder (BPD) indicates promising potential, particularly with compounds such as ketamine and MDMA, which may enhance emotional processing and neuroplasticity. However, systematic exclusion of BPD patients from psychedelic trials has limited available data, highlighting the need for dedicated research in this area.

Full Borderline Personality Disorder (BPD) profile

Academic Research

3 papers
Paywallindividual

An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder

This open-label pilot study (n=9) tested a single dose of psilocybin in adults with borderline personality disorder and major depressive disorder. Depressive symptoms improved over four weeks, but borderline personality disorder symptoms did not change significantly.

Published
April 1, 2026
Journal
Journal of Clinical Psychopharmacology
Authors
Grant, J. E., Boutouis, S., O’Brien, M., Avila, L., Neelapu, M., Ehsan, D.
Open Accessindividual

Effect of psilocybin on empathy and moral decision-making

This placebo-controlled study (n=56) investigated the acute effect of psilocybin (15mg/70kg) on empathy and moral decision-making in healthy human subjects. The results found the first such evidence that psilocybin has distinct effects on social cognition by enhancing emotional empathy but not moral behavior. It also supports previous findings, indicating that psilocybin may promote emotional empathy presumably through activation of serotonin 2A/1A receptors, showing that focusing on serotonin 2A/1A receptors has the potential to treat dysfunctional social cognition.

Published
June 16, 2017
Journal
International Journal of Neuropsychopharmacology
Authors
Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., Vollenweider, F. X.
Open Accessmeta

Ayahuasca: pharmacology, neuroscience and therapeutic potential

This review (2016) examines the pharmacology and neuroscience of ayahuasca, and preliminary findings which indicate the psychological mechanisms associated with its therapeutic benefits are similar to those of mindfulness-based therapy. Ayahuasca appears to enhance self-acceptance and decentering, which converges on evidence from neuroimaging studies that show activation in areas associated with emotional processing and memory formation, thereby enabling individuals to review emotional events with increased vividness and a heightened sense of “reality”. This suggests potential to treat trauma-related conditions and other disorders like borderline personality disorder.

Published
September 1, 2016
Journal
Brain Research Bulletin
Authors
Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., De La Fuente Revenga, M., Friedlander, P., Feilding, A., Riba, J.

Clinical Trials

1 trial
CompletedPhase II

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

Open-label, single-group Phase II study (n=10) assessing a single 25 mg oral dose of psilocybin for adults with MDD and co-occurring BPD to evaluate safety and efficacy.

Started
September 1, 2022
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT05399498

Explore further

Search all Psilocybin papers Search all Borderline Personality Disorder (BPD) trials Full Psilocybin profile Full Borderline Personality Disorder (BPD) profile